Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2026-09-14 19:37:32 ET · period of report 2026-09-14 · accession 0001649904-26-000026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-14 19:37 | 2026-09-14 | RYTM | Meeker David P | Pres, CEO, Dir | M - OptEx | $6.05 | +50.0K | 289.3K | +21% | +$302.5K |
| DMT | 2026-09-14 19:37 | 2026-09-14 | RYTM | Meeker David P | Pres, CEO, Dir | S - Sale+OE | $102.67 | -50.0K | 239.3K | -17% | -$5.13M |
| DT | 2026-09-14 19:37 | 2026-09-14 | RYTM | Meeker David P | Pres, CEO, Dir | M - OptEx | $0.00 | -50.0K | 15.4K | -76% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-14 | M | A | 50,000 | $6.05 | 289,258 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. (F2) Includes 242 shares acquired under the Rhythm Pharmaceuticals, Inc. employee stock purchase plan on 2-28-2026. |
| 2 | Common | Common Stock | 2026-09-14 | S | D | 6,439 | $101.75 | 282,819 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. (F3) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.96 to $101.95 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-09-14 | S | D | 30,746 | $102.35 | 252,073 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. (F4) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.96 to $102.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-09-14 | S | D | 8,698 | $103.43 | 243,375 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. (F5) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.97 to $103.96 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 5 | Common | Common Stock | 2026-09-14 | S | D | 1,817 | $104.55 | 241,558 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. (F6) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.97 to $104.94 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 6 | Common | Common Stock | 2026-09-14 | S | D | 2,300 | $105.19 | 239,258 | D | — | — | (F1) The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2026. (F7) The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.00 to $105.31 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 7 | Derivative | Employee Stock Option (Right to Buy) | 2026-09-14 | M | D | 50,000 | $0.00 | 15,431 | D | $6.05 · — to 2027-02-07 | 50,000 Common Stock | (F8) The stock options were granted on February 8, 2017 and vested and became exercisable in three equal annual installments measured from January 6, 2017. |